{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:51:14Z","timestamp":1787003474149,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The limited number of antifungals and the rising frequency of azole-resistant\n                    <jats:italic>Candida<\/jats:italic>\n                    species are growing challenges to human medicine. Drug repurposing signifies an appealing approach to enhance the activity of current antifungal drugs. Here, we evaluated the ability of Pharmakon 1600 drug library to sensitize an azole-resistant\n                    <jats:italic>Candida albicans<\/jats:italic>\n                    to the effect of fluconazole. The primary screen revealed 44 non-antifungal hits were able to act synergistically with fluconazole against the test strain. Of note, 21 compounds, showed aptness for systemic administration and limited toxic effects, were considered as potential fluconazole adjuvants and thus were termed as \u201crepositionable hits\u201d. A follow-up analysis revealed pitavastatin displaying the most potent fluconazole chemosensitizing activity against the test strain (\u03a3FICI 0.05) and thus was further evaluated against 18 isolates of\n                    <jats:italic>C. albicans<\/jats:italic>\n                    (n\u2009=\u20099),\n                    <jats:italic>C. glabrata<\/jats:italic>\n                    (n\u2009=\u20094), and\n                    <jats:italic>C. auris<\/jats:italic>\n                    (n\u2009=\u20095). Pitavastatin displayed broad-spectrum synergistic interactions with both fluconazole and voriconazole against ~89% of the tested strains (\u03a3FICI 0.05\u20130.5). Additionally, the pitavastatin-fluconazole combination significantly reduced the biofilm-forming abilities of the tested\n                    <jats:italic>Candida<\/jats:italic>\n                    species by up to 73%, and successfully reduced the fungal burdens in a\n                    <jats:italic>Caenorhabditis elegans<\/jats:italic>\n                    infection model by up to 96%. This study presents pitavastatin as a potent azole chemosensitizing agent that warrant further investigation.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-64571-7","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T06:02:48Z","timestamp":1588658568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species"],"prefix":"10.1038","volume":"10","author":[{"given":"Hassan E.","family":"Eldesouky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab A.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony R.","family":"Hazbun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman S.","family":"Mayhoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed N.","family":"Seleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"64571_CR1","doi-asserted-by":"crossref","unstructured":"Nett, J. E. Special Issue: Candida and Candidiasis. J Fungi (Basel) 4 (2018).","DOI":"10.3390\/jof4030074"},{"key":"64571_CR2","doi-asserted-by":"crossref","unstructured":"Sterkel, A., Bateman, A., Valley, A. & Warshauer, D. Viability of Candida auris and Other Candida Species after Various Matrix-Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) Mass Spectrometry-Based Extraction Protocols. J Clin Microbiol 56 (2018).","DOI":"10.1128\/JCM.00886-18"},{"key":"64571_CR3","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1099\/mic.0.000499","volume":"163","author":"NAR Gow","year":"2017","unstructured":"Gow, N. A. R. & Yadav, B. Microbe Profile: Candida albicans: a shape-changing, opportunistic pathogenic fungus of humans. Microbiology 163, 1145\u20131147 (2017).","journal-title":"Microbiology"},{"key":"64571_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55379-1","volume":"9","author":"H Mohammad","year":"2019","unstructured":"Mohammad, H., Eldesouky, H. E., Hazbun, T., Mayhoub, A. S. & Seleem, M. N. Identification of a Phenylthiazole Small Molecule with Dual Antifungal and Antibiofilm Activity Against Candida albicans and Candida auris. Sci Rep 9, 18941 (2019).","journal-title":"Sci Rep"},{"key":"64571_CR5","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/jac\/dkx444","volume":"73","author":"F Lamoth","year":"2018","unstructured":"Lamoth, F., Lockhart, S. R., Berkow, E. L. & Calandra, T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother 73, i4\u2013i13 (2018).","journal-title":"J Antimicrob Chemother"},{"key":"64571_CR6","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1128\/IAI.00469-16","volume":"84","author":"MA Jabra-Rizk","year":"2016","unstructured":"Jabra-Rizk, M. A. et al. Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework. Infection and Immunity 84, 2724\u20132739 (2016).","journal-title":"Infection and Immunity"},{"key":"64571_CR7","doi-asserted-by":"publisher","first-page":"e0120452","DOI":"10.1371\/journal.pone.0120452","volume":"10","author":"AA Cleveland","year":"2015","unstructured":"Cleveland, A. A. et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS One 10, e0120452 (2015).","journal-title":"PLoS One"},{"key":"64571_CR8","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/myc.12206","volume":"57","author":"MA Pfaller","year":"2014","unstructured":"Pfaller, M. A., Jones, R. N. & Castanheira, M. Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011. Mycoses 57, 602\u201311 (2014).","journal-title":"Mycoses"},{"issue":"Suppl 6","key":"64571_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/1469-0691.12539","volume":"20","author":"J Guinea","year":"2014","unstructured":"Guinea, J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect 20(Suppl 6), 5\u201310 (2014).","journal-title":"Clin Microbiol Infect"},{"key":"64571_CR10","doi-asserted-by":"publisher","first-page":"e1007638","DOI":"10.1371\/journal.ppat.1007638","volume":"15","author":"JE Nett","year":"2019","unstructured":"Nett, J. E. Candida auris: An emerging pathogen \u201cincognito\u201d? PLoS Pathog 15, e1007638 (2019).","journal-title":"PLoS Pathog"},{"key":"64571_CR11","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/myc.12904","volume":"62","author":"SA Lone","year":"2019","unstructured":"Lone, S. A. & Ahmad, A. Candida auris-the growing menace to global health. Mycoses 62, 620\u2013637 (2019).","journal-title":"Mycoses"},{"key":"64571_CR12","unstructured":"Centers for Disease Control and Prevention (CDC). Department of Health and Human Services, Antibiotic Resistance Threats in the United States, Atlanta, GA: U.S (2019)."},{"key":"64571_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1021\/acsinfecdis.7b00215","volume":"4","author":"H Mohammad","year":"2018","unstructured":"Mohammad, H. et al. Discovery of a Novel Dibromoquinoline Compound Exhibiting Potent Antifungal and Antivirulence Activity That Targets Metal Ion Homeostasis. ACS Infect Dis 4, 403\u2013414 (2018).","journal-title":"ACS Infect Dis"},{"key":"64571_CR14","first-page":"2173","volume":"7","author":"SG Whaley","year":"2016","unstructured":"Whaley, S. G. et al. Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species. Front Microbiol 7, 2173 (2016).","journal-title":"Front Microbiol"},{"key":"64571_CR15","doi-asserted-by":"publisher","first-page":"e0118770","DOI":"10.1371\/journal.pone.0118770","volume":"10","author":"EJ Won","year":"2015","unstructured":"Won, E. J. et al. Antifungal susceptibilities of bloodstream isolates of Candida species from nine hospitals in Korea: application of new antifungal breakpoints and relationship to antifungal usage. PLoS One 10, e0118770 (2015).","journal-title":"PLoS One"},{"key":"64571_CR16","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1128\/AAC.48.4.1136-1144.2004","volume":"48","author":"JL Song","year":"2004","unstructured":"Song, J. L., Harry, J. B., Eastman, R. T., Oliver, B. G. & White, T. C. The Candida albicans lanosterol 14-alpha-demethylase (ERG11) gene promoter is maximally induced after prolonged growth with antifungal drugs. Antimicrobial Agents and Chemotherapy 48, 1136\u20131144 (2004).","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"64571_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1128\/CMR.12.4.501","volume":"12","author":"MA Ghannoum","year":"1999","unstructured":"Ghannoum, M. A. & Rice, L. B. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clinical Microbiology Reviews 12, 501\u2013+ (1999).","journal-title":"Clinical Microbiology Reviews"},{"key":"64571_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0732-8893(98)00160-6","volume":"33","author":"MA Pfaller","year":"1999","unstructured":"Pfaller, M. A. et al. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagnostic Microbiology and Infectious Disease 33, 217\u2013222 (1999).","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"key":"64571_CR19","doi-asserted-by":"publisher","first-page":"e0150859","DOI":"10.1371\/journal.pone.0150859","volume":"11","author":"S Liu","year":"2016","unstructured":"Liu, S. et al. Synergistic Effect of Fluconazole and Calcium Channel Blockers against Resistant Candida albicans. PLoS One 11, e0150859 (2016).","journal-title":"PLoS One"},{"key":"64571_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/msb.2011.31","volume":"7","author":"M Spitzer","year":"2011","unstructured":"Spitzer, M. et al. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol Syst Biol 7, 499 (2011).","journal-title":"Mol Syst Biol"},{"key":"64571_CR21","doi-asserted-by":"crossref","unstructured":"Eldesouky, H. E., Mayhoub, A., Hazbun, T. R. & Seleem, M. N. Reversal of Azole Resistance in Candida albicans by Sulfa Antibacterial Drugs. Antimicrob Agents Chemother 62 (2018).","DOI":"10.1128\/AAC.00701-17"},{"key":"64571_CR22","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1128\/AAC.06017-11","volume":"56","author":"A Fiori","year":"2012","unstructured":"Fiori, A. & Van Dijck, P. Potent synergistic effect of doxycycline with fluconazole against Candida albicans is mediated by interference with iron homeostasis. Antimicrob Agents Chemother 56, 3785\u201396 (2012).","journal-title":"Antimicrob Agents Chemother"},{"key":"64571_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1128\/AAC.04229-14","volume":"59","author":"K De Cremer","year":"2015","unstructured":"De Cremer, K. et al. Artemisinins, new miconazole potentiators resulting in increased activity against Candida albicans biofilms. Antimicrob Agents Chemother 59, 421\u20136 (2015).","journal-title":"Antimicrob Agents Chemother"},{"key":"64571_CR24","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1128\/AAC.01728-09","volume":"54","author":"S Gamarra","year":"2010","unstructured":"Gamarra, S. et al. Mechanism of the synergistic effect of amiodarone and fluconazole in Candida albicans. Antimicrob Agents Chemother 54, 1753\u201361 (2010).","journal-title":"Antimicrob Agents Chemother"},{"key":"64571_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.riam.2012.09.006","volume":"30","author":"ME Cabral","year":"2013","unstructured":"Cabral, M. E., Figueroa, L. I. C. & Farina, J. I. Synergistic antifungal activity of statin-azole associations as witnessed by Saccharomyces cerevisiae- and Candida utilis-bioassays and ergosterol quantification. Revista Iberoamericana De Micologia 30, 31\u201338 (2013).","journal-title":"Revista Iberoamericana De Micologia"},{"key":"64571_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/1369378031000137233","volume":"41","author":"JL Song","year":"2003","unstructured":"Song, J. L., Lyons, C. N., Holleman, S., Oliver, B. G. & White, T. C. Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans. Med Mycol 41, 417\u201325 (2003).","journal-title":"Med Mycol"},{"key":"64571_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.riam.2012.09.006","volume":"30","author":"ME Cabral","year":"2013","unstructured":"Cabral, M. E., Figueroa, L. I. & Farina, J. I. Synergistic antifungal activity of statin-azole associations as witnessed by Saccharomyces cerevisiae- and Candida utilis-bioassays and ergosterol quantification. Rev Iberoam Micol 30, 31\u20138 (2013).","journal-title":"Rev Iberoam Micol"},{"key":"64571_CR28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.curtheres.2015.02.001","volume":"77","author":"Z Luo","year":"2015","unstructured":"Luo, Z., Zhang, Y., Gu, J., Feng, P. & Wang, Y. Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. Curr Ther Res Clin Exp 77, 52\u20137 (2015).","journal-title":"Curr Ther Res Clin Exp"},{"key":"64571_CR29","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1128\/AAC.41.7.1482","volume":"41","author":"TC White","year":"1997","unstructured":"White, T. C. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41, 1482\u20137 (1997).","journal-title":"Antimicrob Agents Chemother"},{"key":"64571_CR30","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1128\/EC.00221-13","volume":"13","author":"EM Vasicek","year":"2014","unstructured":"Vasicek, E. M., Berkow, E. L., Flowers, S. A., Barker, K. S. & Rogers, P. D. UPC2 is universally essential for azole antifungal resistance in Candida albicans. Eukaryot Cell 13, 933\u201346 (2014).","journal-title":"Eukaryot Cell"},{"key":"64571_CR31","doi-asserted-by":"crossref","first-page":"7115","DOI":"10.1128\/AAC.01061-16","volume":"60","author":"K Koselny","year":"2016","unstructured":"Koselny, K. et al. The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis. Antimicrob Agents Chemother 60, 7115\u20137127 (2016).","journal-title":"Antimicrob Agents Chemother"},{"key":"64571_CR32","doi-asserted-by":"publisher","first-page":"e0195743","DOI":"10.1371\/journal.pone.0195743","volume":"13","author":"Z Khan","year":"2018","unstructured":"Khan, Z. et al. Increasing prevalence, molecular characterization and antifungal drug susceptibility of serial Candida auris isolates in Kuwait. PLoS One 13, e0195743 (2018).","journal-title":"PLoS One"},{"key":"64571_CR33","unstructured":"Centers for Disease Control and Prevention (CDC), Candida auris: Antifungal Susceptibility Testing and Interpretation, https:\/\/www.cdc.gov\/fungal\/candida-auris\/c-auris-antifungal.html (2019)."},{"key":"64571_CR34","doi-asserted-by":"crossref","unstructured":"Arendrup, M.C., Prakash, A., Meletiadis, J., Sharma, C. & Chowdhary, A. Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values. Antimicrob Agents Chemother 61 (2017).","DOI":"10.1128\/AAC.00485-17"},{"key":"64571_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijid.2017.08.017","volume":"63","author":"D Sears","year":"2017","unstructured":"Sears, D. & Schwartz, B. S. Candida auris: An emerging multidrug-resistant pathogen. Int J Infect Dis 63, 95\u201398 (2017).","journal-title":"Int J Infect Dis"},{"key":"64571_CR36","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1128\/JCM.03044-13","volume":"52","author":"AW Fothergill","year":"2014","unstructured":"Fothergill, A. W., Sutton, D. A., McCarthy, D. I. & Wiederhold, N. P. Impact of new antifungal breakpoints on antifungal resistance in Candida species. J Clin Microbiol 52, 994\u20137 (2014).","journal-title":"J Clin Microbiol"},{"key":"64571_CR37","doi-asserted-by":"publisher","first-page":"e28057","DOI":"10.5812\/jjm.28057","volume":"8","author":"G Yenisehirli","year":"2015","unstructured":"Yenisehirli, G., Bulut, N., Yenisehirli, A. & Bulut, Y. In Vitro Susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey. Jundishapur J Microbiol 8, e28057 (2015).","journal-title":"Jundishapur J Microbiol"},{"key":"64571_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1128\/CMR.17.2.255-267.2004","volume":"17","author":"EM Kojic","year":"2004","unstructured":"Kojic, E. M. & Darouiche, R. O. Candida infections of medical devices. Clin Microbiol Rev 17, 255\u201367 (2004).","journal-title":"Clin Microbiol Rev"},{"key":"64571_CR39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-micro-091014-104330","volume":"69","author":"CJ Nobile","year":"2015","unstructured":"Nobile, C. J. & Johnson, A. D. Candida albicans Biofilms and Human Disease. Annu Rev Microbiol 69, 71\u201392 (2015).","journal-title":"Annu Rev Microbiol"},{"key":"64571_CR40","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1567-1364.2006.00117.x","volume":"6","author":"G Ramage","year":"2006","unstructured":"Ramage, G., Martinez, J. P. & Lopez-Ribot, J. L. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res 6, 979\u201386 (2006).","journal-title":"FEMS Yeast Res"},{"key":"64571_CR41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fmed.2018.00028","volume":"5","author":"M Cavalheiro","year":"2018","unstructured":"Cavalheiro, M. & Teixeira, M. C. Candida Biofilms: Threats, Challenges, and Promising Strategies. Front Med (Lausanne) 5, 28 (2018).","journal-title":"Front Med (Lausanne)"},{"key":"64571_CR42","doi-asserted-by":"crossref","unstructured":"Kean, R. et al. Transcriptome Assembly and Profiling of Candida auris Reveals Novel Insights into Biofilm-Mediated Resistance. Msphere 3 (2018).","DOI":"10.1128\/mSphere.00334-18"},{"key":"64571_CR43","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2217\/fmb.13.101","volume":"8","author":"HT Taff","year":"2013","unstructured":"Taff, H. T., Mitchell, K. F., Edward, J. A. & Andes, D. R. Mechanisms of Candida biofilm drug resistance. Future Microbiology 8, 1325\u20131337 (2013).","journal-title":"Future Microbiology"},{"key":"64571_CR44","doi-asserted-by":"crossref","unstructured":"Wuyts, J., Van Dijck, P. & Holtappels, M. Fungal persister cells: The basis for recalcitrant infections? Plos Pathogens 14 (2018).","DOI":"10.1371\/journal.ppat.1007301"},{"key":"64571_CR45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1099\/jmm.0.045054-0","volume":"62","author":"JCO Sardi","year":"2013","unstructured":"Sardi, J. C. O., Scorzoni, L., Bernardi, T., Fusco-Almeida, A. M. & Giannini, M. J. S. M. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. Journal of Medical Microbiology 62, 10\u201324 (2013).","journal-title":"Journal of Medical Microbiology"},{"key":"64571_CR46","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1021\/acs.jmedchem.6b01203","volume":"60","author":"SC Wu","year":"2017","unstructured":"Wu, S. C., Wang, Y., Liu, N., Dong, G. Q. & Sheng, C. Q. Tackling Fungal Resistance by Biofilm Inhibitors. Journal of Medicinal Chemistry 60, 2193\u20132211 (2017).","journal-title":"Journal of Medicinal Chemistry"},{"key":"64571_CR47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3109\/13693786.2011.610037","volume":"50","author":"M Tashiro","year":"2012","unstructured":"Tashiro, M. et al. Pravastatin inhibits farnesol production in Candida albicans and improves survival in a mouse model of systemic candidiasis. Med Mycol 50, 353\u201360 (2012).","journal-title":"Med Mycol"},{"key":"64571_CR48","doi-asserted-by":"crossref","unstructured":"Rybak, J.M. et al. Abrogation of Triazole Resistance upon Deletion of CDR1 in a Clinical Isolate of Candida auris. Antimicrobial Agents and Chemotherapy 63 (2019).","DOI":"10.1128\/AAC.00057-19"},{"key":"64571_CR49","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1128\/AAC.45.4.1174-1183.2001","volume":"45","author":"D Sanglard","year":"2001","unstructured":"Sanglard, D., Ischer, F. & Bille, J. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrobial Agents and Chemotherapy 45, 1174\u20131183 (2001).","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"64571_CR50","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/yea.962","volume":"20","author":"K Izumikawa","year":"2003","unstructured":"Izumikawa, K., Kakeya, H., Tsai, H. F., Grimberg, B. & Bennett, J. E. Function of Candida glabrata ABC transporter gene, PDH1. Yeast 20, 249\u2013261 (2003).","journal-title":"Yeast"},{"key":"64571_CR51","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fphar.2014.00202","volume":"5","author":"R Prasad","year":"2014","unstructured":"Prasad, R. & Rawal, M. K. Efflux pump proteins in antifungal resistance. Front Pharmacol 5, 202 (2014).","journal-title":"Front Pharmacol"},{"key":"64571_CR52","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1128\/EC.3.6.1639-1652.2004","volume":"3","author":"AT Coste","year":"2004","unstructured":"Coste, A. T., Karababa, M., Ischer, F., Bille, J. & Sanglard, D. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell 3, 1639\u201352 (2004).","journal-title":"Eukaryot Cell"},{"key":"64571_CR53","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1371\/journal.ppat.0030164","volume":"3","author":"J Morschhauser","year":"2007","unstructured":"Morschhauser, J. et al. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog 3, e164 (2007).","journal-title":"PLoS Pathog"},{"key":"64571_CR54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/jac\/44.1.27","volume":"44","author":"S Maesaki","year":"1999","unstructured":"Maesaki, S., Marichal, P., Vanden Bossche, H., Sanglard, D. & Kohno, S. Rhodamine 6G efflux for the detection of CDR1-overexpressing azole-resistant Candida albicans strains. Journal of Antimicrobial Chemotherapy 44, 27\u201331 (1999).","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"64571_CR55","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.1128\/AAC.03046-15","volume":"60","author":"WR Gu","year":"2016","unstructured":"Gu, W. R., Guo, D. M., Zhang, L. P., Xu, D. M. & Sun, S. J. The Synergistic Effect of Azoles and Fluoxetine against Resistant Candida albicans Strains Is Attributed to Attenuating Fungal Virulence. Antimicrobial Agents and Chemotherapy 60, 6179\u20136188 (2016).","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"64571_CR56","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/jam.12737","volume":"118","author":"LM Sun","year":"2015","unstructured":"Sun, L. M., Liao, K., Liang, S., Yu, P. H. & Wang, D. Y. Synergistic activity of magnolol with azoles and its possible antifungal mechanism against Candida albicans. J Appl Microbiol 118, 826\u201338 (2015).","journal-title":"J Appl Microbiol"},{"key":"64571_CR57","doi-asserted-by":"publisher","first-page":"e57672","DOI":"10.1371\/journal.pone.0057672","volume":"8","author":"YL Chen","year":"2013","unstructured":"Chen, Y. L., Lehman, V. N., Averette, A. F., Perfect, J. R. & Heitman, J. Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans. PLoS One 8, e57672 (2013).","journal-title":"PLoS One"},{"key":"64571_CR58","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1128\/AAC.02040-12","volume":"57","author":"LV Silva","year":"2013","unstructured":"Silva, L. V. et al. Milbemycins: more than efflux inhibitors for fungal pathogens. Antimicrob Agents Chemother 57, 873\u201386 (2013).","journal-title":"Antimicrob Agents Chemother"},{"key":"64571_CR59","doi-asserted-by":"crossref","unstructured":"Keniya, M. V., Fleischer, E., Klinger, A., Cannon, R. D. & Monk, B. C. Inhibitors of the Candida albicans Major Facilitator Superfamily Transporter Mdr1p Responsible for Fluconazole Resistance. Plos One 10 (2015).","DOI":"10.1371\/journal.pone.0126350"},{"key":"64571_CR60","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ab.2009.07.001","volume":"394","author":"I Ivnitski-Steele","year":"2009","unstructured":"Ivnitski-Steele, I. et al. Identification of Nile red as a fluorescent substrate of the Candida albicans ATP-binding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Mdr1p. Analytical Biochemistry 394, 87\u201391 (2009).","journal-title":"Analytical Biochemistry"},{"key":"64571_CR61","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.ijantimicag.2018.08.016","volume":"52","author":"HE Eldesouky","year":"2018","unstructured":"Eldesouky, H. E., Li, X., Abutaleb, N. S., Mohammad, H. & Seleem, M. N. Synergistic interactions of sulfamethoxazole and azole antifungal drugs against emerging multidrug-resistant Candida auris. Int J Antimicrob Agents 52, 754\u2013761 (2018).","journal-title":"Int J Antimicrob Agents"},{"key":"64571_CR62","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1083\/jcb.100.3.965","volume":"100","author":"P Greenspan","year":"1985","unstructured":"Greenspan, P., Mayer, E. P. & Fowler, S. D. Nile red: a selective fluorescent stain for intracellular lipid droplets. J Cell Biol 100, 965\u201373 (1985).","journal-title":"J Cell Biol"},{"key":"64571_CR63","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1128\/AAC.45.12.3366-3374.2001","volume":"45","author":"K Nakamura","year":"2001","unstructured":"Nakamura, K. et al. Functional expression of Candida albicans drug efflux pump Cdr1p in a Saccharomyces cerevisiae strain deficient in membrane transporters. Antimicrob Agents Chemother 45, 3366\u201374 (2001).","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64571-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64571-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64571-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T05:05:57Z","timestamp":1670303157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64571-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["64571"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-64571-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/696773","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,5]]},"assertion":[{"value":"13 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7525"}}